April 21 Newsletter
Hem Onc Newsletter April 2021
Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size
Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size
April 21 Active Clinical Trials
April 2021 Clinical Trials Brochure
Dr. Vaishali Sanchorawala discusses results from Phase III ANDROMEDA study: daratumumab plus VCd in AL amyloidosis
March 21 Newsletter
Hem-Onc Newsletter March 21
New Chief Fellows 2021-2022
We are pleased to announce that Drs. Karen Axten and Andrew Staron have accepted chief fellow positions for next year. They have big shoes to fill as Raphael and Meredith have done a remarkable job this year — overseeing a curriculum revision, helping support one another through an unprecedented pandemic, and helping with a very […]
Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors
Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors
March 21 Active Clinical Trials
March 2021 Clinical Trials Brochure
February 21 Newsletter
Hem Onc Newsletter-Feb 21